– Reuters
JP Morgan Maintains Overweight on Sage Therapeutics, Lowers Price Target to $60
JP Morgan analyst Anupam Rama maintains Sage Therapeutics (NASDAQ:SAGE) with a Overweight and lowers the price target from $92 to $60.
Related Posts
20% Of US Monkeypox Cases Are In This City
New York City has become the monkeypox capital of the U.S., with nearly 20% of the nation’s reported cases.
What Happened: According to the New York Post, the city recorded 119 cases as of Wednesday. That's up 50% from last week.
Here’s How Much You Would Have Made Owning Caterpillar Stock In The Last 20 Years
Caterpillar (NYSE:CAT) has outperformed the market over the past 20 years by 3.49% on an annualized basis producing an average annual return of 11.5%. Currently, Caterpillar has a market capitalization of $99.81 billion.
Why Alibaba Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session
Shares of Alibaba Group Holding Limited (NYSE:BABA) fell sharply during Tuesday’s session following mixed first-quarter financial results. The…